Enzymatica AB (publ) (ENZY.ST)
SEK 3.4
(0.0%)
SEK 3.4
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 125.91 Million SEK | -27.81% |
| 2022 | 174.41 Million SEK | 11.06% |
| 2021 | 157.04 Million SEK | -3.08% |
| 2020 | 162.02 Million SEK | 9.69% |
| 2019 | 147.71 Million SEK | -20.23% |
| 2018 | 185.17 Million SEK | 38.37% |
| 2017 | 133.82 Million SEK | -17.72% |
| 2016 | 162.64 Million SEK | 270.89% |
| 2015 | 43.85 Million SEK | -39.24% |
| 2014 | 72.16 Million SEK | 177.38% |
| 2013 | 26.01 Million SEK | 62.39% |
| 2012 | 16.02 Million SEK | 245.0% |
| 2011 | 4.64 Million SEK | 0.0% |
| 2009 | 1.22 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 116.16 Million SEK | -15.25% |
| 2024 Q1 | 137.06 Million SEK | 8.86% |
| 2023 Q2 | 143.58 Million SEK | -5.68% |
| 2023 Q1 | 152.22 Million SEK | -12.72% |
| 2023 FY | 125.91 Million SEK | -27.81% |
| 2023 Q4 | 125.91 Million SEK | -9.98% |
| 2023 Q3 | 139.86 Million SEK | -2.59% |
| 2022 Q4 | 174.41 Million SEK | -13.27% |
| 2022 Q1 | 136.97 Million SEK | -12.78% |
| 2022 FY | 174.41 Million SEK | 11.06% |
| 2022 Q3 | 201.09 Million SEK | 54.19% |
| 2022 Q2 | 130.42 Million SEK | -4.78% |
| 2021 FY | 157.04 Million SEK | -3.08% |
| 2021 Q4 | 157.04 Million SEK | -9.34% |
| 2021 Q2 | 182.07 Million SEK | 24.3% |
| 2021 Q1 | 146.48 Million SEK | -9.6% |
| 2021 Q3 | 173.21 Million SEK | -4.87% |
| 2020 Q2 | 147.65 Million SEK | -8.19% |
| 2020 Q3 | 149.99 Million SEK | 1.58% |
| 2020 Q4 | 162.02 Million SEK | 8.03% |
| 2020 FY | 162.02 Million SEK | 9.69% |
| 2020 Q1 | 160.82 Million SEK | 8.88% |
| 2019 FY | 147.71 Million SEK | -20.23% |
| 2019 Q1 | 168.92 Million SEK | -8.78% |
| 2019 Q2 | 149.53 Million SEK | -11.48% |
| 2019 Q3 | 148.43 Million SEK | -0.73% |
| 2019 Q4 | 147.71 Million SEK | -0.49% |
| 2018 Q1 | 124.51 Million SEK | -6.95% |
| 2018 FY | 185.17 Million SEK | 38.37% |
| 2018 Q3 | 127.5 Million SEK | 10.18% |
| 2018 Q2 | 115.72 Million SEK | -7.06% |
| 2018 Q4 | 185.17 Million SEK | 45.23% |
| 2017 Q3 | 138.44 Million SEK | 1.06% |
| 2017 Q1 | 147.66 Million SEK | -9.21% |
| 2017 Q4 | 133.82 Million SEK | -3.34% |
| 2017 FY | 133.82 Million SEK | -17.72% |
| 2017 Q2 | 136.99 Million SEK | -7.22% |
| 2016 Q4 | 162.64 Million SEK | -11.01% |
| 2016 FY | 162.64 Million SEK | 270.89% |
| 2016 Q2 | 149.9 Million SEK | 268.23% |
| 2016 Q3 | 182.77 Million SEK | 21.92% |
| 2016 Q1 | 40.71 Million SEK | -7.16% |
| 2015 Q3 | 43.54 Million SEK | -23.85% |
| 2015 Q2 | 57.18 Million SEK | -5.51% |
| 2015 Q4 | 43.85 Million SEK | 0.7% |
| 2015 Q1 | 60.51 Million SEK | -16.14% |
| 2015 FY | 43.85 Million SEK | -39.24% |
| 2014 Q2 | 90.13 Million SEK | 364.03% |
| 2014 Q4 | 72.16 Million SEK | -13.91% |
| 2014 Q3 | 83.83 Million SEK | -6.99% |
| 2014 FY | 72.16 Million SEK | 177.38% |
| 2014 Q1 | 19.42 Million SEK | -25.34% |
| 2013 Q4 | 26.01 Million SEK | -2.21% |
| 2013 Q3 | 26.6 Million SEK | 147.07% |
| 2013 FY | 26.01 Million SEK | 62.39% |
| 2013 Q1 | 14.45 Million SEK | -9.8% |
| 2013 Q2 | 10.76 Million SEK | -25.48% |
| 2012 Q2 | 11.18 Million SEK | 254.89% |
| 2012 Q3 | 17.69 Million SEK | 58.09% |
| 2012 Q1 | 3.15 Million SEK | 0.0% |
| 2012 Q4 | 16.02 Million SEK | -9.43% |
| 2012 FY | 16.02 Million SEK | 245.0% |
| 2011 FY | 4.64 Million SEK | 0.0% |
| 2011 Q3 | 6.15 Million SEK | -20.07% |
| 2011 Q2 | 7.7 Million SEK | 0.0% |
| 2009 FY | 1.22 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | -115.207% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | -293.46% |
| BioGaia AB (publ) | 2.33 Billion SEK | 94.603% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | -266.18% |
| Gabather AB (publ) | 2.93 Million SEK | -4187.062% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | -72.198% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | 80.163% |
| Nanexa AB (publ) | 132.25 Million SEK | 4.798% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | -38.56% |
| ODI Pharma AB | 12.27 Million SEK | -925.752% |
| Orexo AB (publ) | 786.6 Million SEK | 83.993% |
| Probi AB (publ) | 1.55 Billion SEK | 91.879% |
| Swedencare AB (publ) | 9.52 Billion SEK | 98.678% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.83% |
| Toleranzia AB | 160.42 Million SEK | 21.515% |
| Vivesto AB | 355.87 Million SEK | 64.619% |